# OnCo record nct07006727 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07006727/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07006727", "NCT07006727" ;
  schema:name "Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors"@en ;
  schema:description "A phase 1 trial of [225Ac]Ac-ETN029 run by Novartis Pharmaceuticals, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07006727/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07006727> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/lung-lcnec/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/extrapulmonary-nec/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/medullary-thyroid-cancer/> ;
  onco:drugs <https://onco.cc/drugs/etn029/> ;
  onco:companies <https://onco.cc/companies/mariana-oncology/>, <https://onco.cc/companies/novartis/> .